SEC Form 4 · accession 0001209191-15-053752
Coherus Oncology, Inc. · CHRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
August J. Troendle
Director
Period of report
Jun 12, 2015
Accepted (ET)
Jun 16, 2015 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001512762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Jun 12, 2015 | S | 134,167 | $26.7223 | D | 2,008,325 | I | See Footnote |
| Common Stock, $0.0001 par valueF3,F2 | Jun 12, 2015 | S | 1,851 | $27.2893 | D | 2,006,474 | I | See Footnote |
| Common Stock, $0.0001 par valueF4,F2 | Jun 15, 2015 | S | 111,606 | $26.6167 | D | 1,894,868 | I | See Footnote |
| Common Stock, $0.0001 par valueF5,F2 | Jun 15, 2015 | S | 2,376 | $27.0753 | D | 1,892,492 | I | See Footnote |
| Common Stock, $0.0001 par value | holding | — | — | — | 21,870 | D | ||
| Common Stock, $0.0001 par valueF6 | holding | — | — | — | 358,428 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction was executed in multiple trades in prices ranging from $26.08 to $27.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F2The shares are held by MX II Associates LLC ("MX II Associates"). Reporting Person is the Managing Member of MX II Associates. Voting and dispositive decisions with respect to shares held by MX II Associates are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by MX II Associates, except to the extent of any pecuniary interest therein.
- F3The transaction was executed in multiple trades in prices ranging from $27.08 to $27.52, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F4The transaction was executed in multiple trades in prices ranging from $26.00 to $26.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F5The transaction was executed in multiple trades in prices ranging from $27.00 to $27.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- F6The shares are held by Medpace Investors, LLC ("Medpace Investors"). Reporting Person is the Manager of Medpace Investors. Voting and dispositive decisions with respect to shares held by Medpace Investors are made by Reporting Person, however, Reporting Person disclaims beneficial ownership of the shares held by Medpace Investors, except to the extent of any pecuniary interest therein.